Use of more clinically relevant models of insulin resistance (such as defects in insulin receptor or post-receptor signaling components) should help to better understand the role of PGC-1α and its post-translational modification in the progression of insulin resistance-induced cardiomyopathy. This evidence concerns the gene PPARGC1A and Insulin resistance.